Literature DB >> 8752154

Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells.

T Seufferlein1, E Rozengurt.   

Abstract

The serine/threonine kinase p70s6k was found to be constitutively phosphorylated in H 69, H 345, and H 510 small cell lung cancer cells as judged by the retarded electrophoretic mobility of both isoforms of this kinase. Pretreatment of H 69, H 345, and H 510 cells with the potent immunosuppressant rapamycin led to p70s6k dephosphorylation in a concentration-dependent manner; half-maximum and maximum effects were achieved at 0.3 and 3 nM rapamycin, respectively. Rapamycin inhibited growth of H 69, H 345, and H 510 cells in liquid culture at similar concentrations to those required for inducing dephosphorylation of p70s6k. Furthermore, rapamycin markedly reduced the basal colony forming ability of H 69, H 345, and H 510 cells in semisolid media. Thus, constitutively phosphorylated/active p70s6k plays an important role in promoting the growth of small cell lung cancer cells. Furthermore, the rapamycin-sensitive p70s6k pathway may provide a novel target for therapeutic intervention in small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752154

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  mTOR signaling in cancer cell motility and tumor metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

Review 2.  Role of mTOR signaling in tumor cell motility, invasion and metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Curr Protein Pept Sci       Date:  2011-02       Impact factor: 3.272

Review 3.  mTOR function and therapeutic targeting in breast cancer.

Authors:  Stephen H Hare; Amanda J Harvey
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

4.  Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.

Authors:  David A Reardon; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; Allan H Friedman; James E Herndon; Jennifer Marcello; Julie A Norfleet; Roger E McLendon; John H Sampson; Henry S Friedman
Journal:  J Neurooncol       Date:  2009-06-28       Impact factor: 4.130

5.  The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells.

Authors:  C T Bussiere; J R T Lakey; A M J Shapiro; G S Korbutt
Journal:  Diabetologia       Date:  2006-08-09       Impact factor: 10.122

Review 6.  Updates of mTOR inhibitors.

Authors:  Hongyu Zhou; Yan Luo; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2010-09       Impact factor: 2.505

7.  Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth.

Authors:  Guido Schumacher; Marijke Oidtmann; Anne Rueggeberg; Dietmar Jacob; Sven Jonas; Jan-M Langrehr; Ruth Neuhaus; Marcus Bahra; Peter Neuhaus
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

Review 8.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

9.  Repeated aerosol delivery of carboxyl-terminal modulator protein suppresses tumor in the lungs of K-rasLA1 mice.

Authors:  Soon-Kyung Hwang; Hwang-Tae Lim; Arash Minai-Tehrani; Eun-Sun Lee; Jongmin Park; Seung Bum Park; George R Beck; Myung-Haing Cho
Journal:  Am J Respir Crit Care Med       Date:  2009-03-12       Impact factor: 21.405

10.  Targeting of protein translation as a new treatment paradigm for prostate cancer.

Authors:  Vidya P Ramamurthy; Senthilmurugan Ramalingam; Andrew K Kwegyir-Afful; Arif Hussain; Vincent C O Njar
Journal:  Curr Opin Oncol       Date:  2017-05       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.